PARIS, March 21, 2016 /PRNewswire/ -- BioNet-Asia, an innovative clinical stage vaccine company, announced the formation of BioNet Scientific Advisory Board (SAB), under the chairmanship of Emeritus Prof. Dr. Stanley Plotkin. The mission of BioNet SAB will be to provide valuable scientific advice, along with strategic guidance on its recombinant pertussis vaccine pipeline while the company is advancing rapidly with its clinical development.
The following members, well-known experts in the field of pertussis vaccinology, were appointed during BioNet's first Scientific Advisory Board meeting held in Paris on March 3rd, 2016:
"We are honored to welcome such eminent scientists to our advisory board to support BioNet pertussis clinical development programs," said Pham Hong Thai, the Chief Executive Officer of BioNet. Dr. Stanley Plotkin commented: "I am pleased to chair the Scientific Advisory Board of BioNet and to support BioNet in developing a new generation of pertussis vaccines which has the potential to control the resurgence of pertussis in the world."
About BioNet-Asia
BioNet-Asia is a clinical-stage biotech company with a focus on technological innovation and global market access. BioNet is developing a broad pipeline of recombinant vaccines in its state-of-the-art facilities in Thailand. BioNet's first genetically-engineered pertussis vaccines are now being evaluated in Phase II/III clinical trials. The company has also built global manufacturing alliances leading to the supply of billions of doses of vaccines worldwide.
Photo - http://photos.prnasia.com/prnh/20160321/8521601856LOGO
For further information, please contact:
BioNet-Asia Co., Ltd.
Mr Laurent Dapremont
Director, Strategic Business Development
E-mail: info@bionet-asia.com
www.bionet-asia.com